论文部分内容阅读
目的观察及评价沙利度胺预防顺铂化疗所致的迟发性呕吐的临床疗效及安全性。方法选取2013年9月至2014年9月收治的接受高催吐药物顺铂治疗的肿瘤患者45例,共化疗70例次,随机分为观察组(35例次)和对照组(35例次)。观察组自化疗当天起予以口服沙利度胺,持续1周,对照组未使用沙利度胺。观察两组迟发性呕吐发生率,并进行统计学分析。结果观察组与对照组第2天、第3天、第4天、第5天的迟发性呕吐的发生情况差异均有统计学意义(P均<0.05)。两组深静脉血栓、骨髓抑制、肝肾功能损害、便秘、周围神经炎发生率比较,差异均无统计学意义(P均>0.05)。结论沙利度胺对顺铂所致的迟发性呕吐有效,用药安全,沙利度胺临床抗肿瘤治疗的适应证进一步扩大。
Objective To observe and evaluate the clinical efficacy and safety of thalidomide in preventing delayed emesis caused by cisplatin chemotherapy. Methods Forty-five patients with tumors treated with cisplatin, a high-emetic drug, were enrolled in this study from September 2013 to September 2014. The patients were randomly divided into observation group (35 cases) and control group (35 cases) . The observation group was given thalidomide orally from the day of chemotherapy for 1 week, while thalidomide was not used in the control group. The incidence of delayed emesis in both groups was observed and statistically analyzed. Results The incidence of delayed emesis in observation group and control group on day 2, day 3, day 4 and day 5 were all statistically significant (all P <0.05). The incidence of deep vein thrombosis, myelosuppression, liver and kidney dysfunction, constipation and peripheral neuritis were not significantly different between the two groups (all P> 0.05). Conclusions Thalidomide is effective in the delayed emesis caused by cisplatin. The safety of drugs and the indications of thalidomide in clinical anti-tumor therapy are further expanded.